Profile data is unavailable for this security.
About the company
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
- Revenue in USD (TTM)399.58m
- Net income in USD-54.04m
- Incorporated2006
- Employees815.00
- LocationVeracyte Inc6000 Shoreline Court, Suite 300SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 243-6300
- Fax+1 (650) 243-6301
- Websitehttps://www.veracyte.com/
More ▼
Mergers & acquisitions
| Acquired company | VCYT:NMQ since announced | Transaction value |
|---|---|---|
| C2i Genomics Inc | 31.64% | 95.00m |
Data delayed at least 15 minutes, as of Oct 07 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janux Therapeutics Inc | 15.13m | -44.05m | 2.35bn | 64.00 | -- | 3.57 | -- | 155.25 | -0.9152 | -0.9152 | 0.3088 | 12.61 | 0.0293 | -- | -- | 236,359.40 | -8.53 | -- | -8.78 | -- | -- | -- | -291.17 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 31.31m | -364.93m | 2.35bn | 383.00 | -- | 3.56 | -- | 75.10 | -6.49 | -6.49 | 0.5568 | 11.61 | 0.0337 | 0.1687 | 10.41 | 81,738.91 | -39.28 | -29.54 | -41.94 | -31.88 | 89.33 | -- | -1,165.69 | -3,826.10 | 9.71 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Azenta Inc | 658.62m | -156.38m | 2.36bn | 3.30k | -- | 1.22 | -- | 3.59 | -2.82 | -2.81 | 11.73 | 39.50 | 0.2443 | 3.08 | 3.49 | 188,176.30 | -5.80 | -0.5934 | -6.27 | -0.6725 | 39.78 | 43.08 | -23.74 | -2.17 | 4.21 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Neumora Therapeutics Inc | 0.00 | -274.18m | 2.36bn | 108.00 | -- | 6.19 | -- | -- | -1.66 | -1.66 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -71.73 | -- | -76.67 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Immunitybio Inc | 1.31m | -597.65m | 2.39bn | 622.00 | -- | -- | -- | 1,826.54 | -0.9356 | -0.9356 | 0.0021 | -1.01 | 0.0036 | -- | 0.49 | 2,082.80 | -162.54 | -112.76 | -1,927.61 | -316.07 | -- | -- | -45,701.07 | -37,700.74 | 3.88 | -2.33 | 3.69 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| SpringWorks Therapeutics Inc | 86.19m | -301.06m | 2.42bn | 305.00 | -- | 4.35 | -- | 28.13 | -4.44 | -4.44 | 1.25 | 7.50 | 0.1519 | -- | -- | 282,577.10 | -53.07 | -36.97 | -57.99 | -39.49 | 95.27 | -- | -349.32 | -2,176.46 | 7.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| CG Oncology Inc | 650.00k | -75.84m | 2.46bn | 61.00 | -- | 4.42 | -- | 3,780.05 | -1.17 | -1.17 | 0.01 | 8.29 | -- | -- | -- | 10,655.74 | -- | -- | -- | -- | -- | -- | -9,870.92 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -100.44m | 2.46bn | 136.00 | -- | 2.67 | -- | -- | -2.24 | -2.24 | 0.00 | 16.10 | 0.00 | -- | -- | 0.00 | -17.07 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 890.53m | 30.57m | 2.50bn | 630.00 | 83.28 | 4.85 | 59.60 | 2.81 | 0.1813 | 0.1813 | 5.38 | 3.12 | 1.14 | 1.83 | 9.60 | 1,491,682.00 | 3.93 | -27.50 | 5.93 | -32.73 | 91.72 | 95.62 | 3.43 | -38.35 | 1.95 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Veracyte Inc | 399.58m | -54.04m | 2.52bn | 815.00 | -- | 2.23 | -- | 6.31 | -0.7444 | -0.7444 | 5.37 | 14.76 | 0.3336 | 8.11 | 8.62 | 490,281.00 | -4.51 | -6.33 | -4.77 | -6.69 | 68.73 | 67.10 | -13.52 | -20.99 | 4.17 | -- | 0.00009 | -- | 21.76 | 31.45 | -103.51 | -- | 39.67 | -- |
| Ideaya Biosciences Inc | 11.96m | -153.74m | 2.53bn | 124.00 | -- | 2.45 | -- | 211.70 | -2.18 | -2.18 | 0.1718 | 12.24 | 0.0159 | -- | 148.57 | 96,451.61 | -20.48 | -19.17 | -21.42 | -21.05 | -- | -- | -1,285.44 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Geron Corp | 1.37m | -219.55m | 2.60bn | 141.00 | -- | 8.47 | -- | 1,896.63 | -0.3595 | -0.3595 | 0.0023 | 0.5103 | 0.0032 | -- | 0.6367 | 9,737.59 | -50.78 | -51.32 | -63.77 | -64.90 | 63.00 | -- | -15,990.60 | -19,949.13 | 3.60 | -- | 0.2139 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Protagonist Therapeutics Inc | 319.12m | 169.95m | 2.61bn | 125.00 | 16.83 | 4.82 | 15.29 | 8.19 | 2.64 | 2.64 | 5.22 | 9.21 | 0.6825 | -- | 449.46 | 2,849,286.00 | 36.35 | -35.90 | 39.20 | -41.36 | -- | -- | 53.26 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| Edgewise Therapeutics Inc | 0.00 | -115.88m | 2.66bn | 97.00 | -- | 5.21 | -- | -- | -1.53 | -1.53 | 0.00 | 5.45 | 0.00 | -- | -- | 0.00 | -26.88 | -- | -27.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| PTC Therapeutics, Inc. | 900.45m | -479.52m | 2.70bn | 988.00 | -- | -- | -- | 3.00 | -6.32 | -6.32 | 11.84 | -12.75 | 0.5534 | 2.16 | 4.94 | 911,390.70 | -29.47 | -26.71 | -44.23 | -33.46 | 92.35 | 93.94 | -53.25 | -83.80 | 2.17 | -1.16 | 1.70 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
Data as of Oct 07 2024. Currency figures normalised to Veracyte Inc's reporting currency: US Dollar USD
60.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 7.26m | 9.50% |
| ARK Investment Management LLCas of 30 Jun 2024 | 6.81m | 8.91% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 6.79m | 8.88% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.89m | 7.70% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.33m | 5.66% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 3.29m | 4.31% |
| Nikko Asset Management Americas, Inc.as of 30 Jun 2024 | 3.18m | 4.16% |
| Artisan Partners LPas of 31 Mar 2024 | 3.08m | 4.03% |
| Champlain Investment Partners LLCas of 31 Mar 2024 | 2.70m | 3.53% |
| ArrowMark Colorado Holdings LLCas of 31 Mar 2024 | 2.64m | 3.46% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
